questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of levels of regional variation in access to fezolinetant across England.
answerText: The National Institute for Health and Care Excellence (NICE) published guidance on 31 March 2026 recommending fezolinetant as an option for treating moderate to severe menopause-related hot flushes and night sweats when hormone replacement therapy is unsu...
heading: Fezolinetant